Such publication commonly leads to urgent calls to take immediate regulatory action, without acknowledgment of potential pitfalls in the interpretation of data from meta-analyses and pooled analyses, such as those encountered in the tiotropium evaluation.

FORBES: FDA Asks For "Restraint" On Drug Safety Worries